Private equity project

Mikrochem

Investment in the production of active pharmaceutical ingredients and pure special chemicals.

About the project

At the beginning of 2019, we invested in the Mikrochem Group’s companies that produce:

  • pure and special chemicals
  • active pharmaceutical ingredients, so-called “APIs” used in pharmaceuticals
  • liquid non-sterile medicines for internal and external treatment
  • other drugs, pharmaceutical raw materials, industrial and technical chemicals, special molecular distillations, and syntheses according to customer requirements

The founder and executive director of Mikrochem is RNDr. Juraj Čech, who founded the company in 1990, after working several years in the Chemical Plants of Juraj Dimitrov (today’s Istrochem Group). The company has its own production and storage facilities in Pezinok. Its customers include leading pharmaceutical companies in the European and global markets.

Mikrochem Group structure also includes Mikrochem Trade and Mikrochem Energy. The subsidiary Mikrochem Trade focuses primarily on the sale of chemical products for laboratory activities and industrial production, raw materials and products in food quality, laboratory aids of specialised laboratory measuring equipment. Mikrochem Energy operates a cogeneration source intended for the production of electricity and heat for its own production process. The company has several key products in its portfolio on which it plans to build its further development. Besides the production of standardised active pharmaceutical ingredients, we see potential in the development and production of tailor-made solutions for the needs of leading players in the pharmaceutical industry. The medium-term goal over a five-year horizon is to significantly expand the portfolio of APIs produced and to multiply sales of products, especially Methylene Blue and subsequently D-mannose. We see considerable potential in the production of pure and special chemicals, active pharmaceutical ingredients, and medicines. We are convinced that Mikrochem has all the prerequisites to benefit from the growing demand for quality pharmaceutical raw materials.

Current status

Investment horizon
2019 2020 2021 2022 2023 2024 2025
Current project phase
Acquisition Preparation Permitting Construction Investment Exit Completed

Benefits

  • Mikrochem neustále vylepšuje svoju výskumno-vývojovú kapacitu a vďaka tomu sa postupne transformuje na spoločnosť venujúcu sa primárne vývoju a výrobe aktívnych farmaceutických prísad

  • trh s „API“ sa vyznačuje značnými bariérami vstupu, jeho výhodou však je, že pri úspešnom prerazení a udržaní si dostatočnej kvality poskytuje stabilitu odberateľov

  • popri výrobe štandardizovaných aktívnych farmaceutických prísad, vidíme potenciál vo vývoji a výrobe na mieru šitých riešení pre potreby popredných hráčov vo farmaceutickom priemysle